Log in to see the prices.
The price above is a net price.
The Akkermansia muciniphila/Faecalibacterium prausnitzii (qPCR) product is used to determine sequences specific to Akkermansia muciniphila/Faecalibacterium prausnitzii bacteria Akkermansia muciniphila and Faecalibacterium prausnitzii in DNA preparations obtained from human feces.
Kit size: 100 reactions
Reaction: triplex (FAM: Akkermansia muciniphila, Texas Red: Faecalibacterium prausnitzii, HEX: internal control)
Internal control: exogenous/endogenous
Determination: qualitative/quantitative
Kit components:
For the purpose of this product, the species Akkermansia muciniphila is defined according to the original nomenclature. It includes bacterial strains that, according to the current nomenclature, are assigned to the species: A. muciniphila, A. massiliensis, and Candidatus Akkermansia timonensis/Akkermansia biwaensis. The species Faecalibacterium prausnitzii, on the other hand, is defined according to the new nomenclature and includes strains that are part of group 1 Faecalibacterium prausnitzii according to the original nomenclature.
Both species of bacteria colonize the human digestive system. A. muciniphila is abundant in the gut microbiome of healthy individuals and has preventive and therapeutic effects on obesity, type 2 diabetes, and other metabolic disorders. Its abundance is inversely proportional to the body weight of mice and humans. Reduced levels of A. muciniphila are also observed in patients with inflammatory bowel disease (mainly ulcerative colitis) and metabolic disorders. The level of this bacterium is reduced in obese children and adults. There is also evidence that A. muciniphila regulates energy homeostasis and glucose metabolism.
F. prausnitzii is a promising biomarker of healthy human microbiota. This bacterium metabolizes carbohydrates in the human intestine, producing butyrate. This compound is the main source of energy for intestinal epithelial cells and has many beneficial properties for the health of the host. It has a beneficial effect on various pathways, including the regulation of histone acetylation and mitogen-activated protein kinases.
The absence or reduced amount of Faecalibacterium prausnitzii bacteria in the intestines is associated with the development and more severe course of several diseases, including inflammatory bowel disease (IBD), metabolic disorders, and mental disorders. Recent studies on the composition of the gut microbiota in people with various heart conditions have shown a significant reduction in the number of F. prausnitzii. This suggests that this microbe may play a key role in inhibiting the formation of atherosclerotic plaques.
